ATAI Life Sciences/$ATAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Ticker
$ATAI
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
54
Website
ATAI Metrics
BasicAdvanced
$870M
-
-$0.91
1.22
-
Price and volume
Market cap
$870M
Beta
1.22
52-week high
$4.29
52-week low
$1.03
Average daily volume
7.3M
Financial strength
Current ratio
4.069
Quick ratio
3.498
Long term debt to equity
9.317
Total debt to equity
19.024
Interest coverage (TTM)
-23.60%
Profitability
EBITDA (TTM)
-96.251
Gross margin (TTM)
121.04%
Net profit margin (TTM)
-7,997.16%
Operating margin (TTM)
-5,096.99%
Effective tax rate (TTM)
0.50%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-25.53%
Return on equity (TTM)
-79.43%
Valuation
Price to revenue (TTM)
362.063
Price to book
5.39
Price to tangible book (TTM)
5.51
Price to free cash flow (TTM)
-8.558
Free cash flow yield (TTM)
-11.69%
Free cash flow per share (TTM)
-0.479
Growth
Revenue change (TTM)
572.56%
Earnings per share change (TTM)
327.65%
3-year revenue growth (CAGR)
55.45%
3-year earnings per share growth (CAGR)
-13.49%
What the Analysts think about ATAI
Analyst ratings (Buy, Hold, Sell) for ATAI Life Sciences stock.
Bulls say / Bears say
Positive Phase 2b results for BPL-003 in treatment-resistant depression indicate strong efficacy and safety, potentially leading to regulatory approval and market adoption. (ft.com)
The $50 million private placement financing enhances atai's financial position, supporting ongoing and future clinical trials. (atai.gcs-web.com)
The acquisition of Beckley Psytech for $390 million positions atai as a leader in psychedelic mental health therapies, expanding its pipeline and market reach. (ft.com)
Shares have declined 89% since the 2021 IPO, reflecting investor skepticism and market volatility in the psychedelic drug sector. (ft.com)
The company reported a net loss of $149.3 million in 2024, up from $40.2 million in 2023, indicating increasing financial strain. (stocktitan.net)
Despite promising clinical results, the psychedelic drug sector remains financially volatile, with many companies not yet generating sales, posing risks to atai's financial stability. (ft.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
ATAI Financial Performance
Revenues and expenses
ATAI Earnings Performance
Company profitability
ATAI News
AllArticlesVideos
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga·4 days ago
atai eyes 2025 catalysts in psychedelic portfolio following Recognify trial update
Proactive Investors·4 days ago
Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial
Reuters·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ATAI Life Sciences stock?
ATAI Life Sciences (ATAI) has a market cap of $870M as of August 01, 2025.
What is the P/E ratio for ATAI Life Sciences stock?
The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of August 01, 2025.
Does ATAI Life Sciences stock pay dividends?
No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next ATAI Life Sciences dividend payment date?
ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.
What is the beta indicator for ATAI Life Sciences?
ATAI Life Sciences (ATAI) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.